Navigation Links
Multiple Programs from Merrimack Pharmaceuticals' Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:11/11/2011

CAMBRIDGE, Mass., Nov. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that they will present seven posters on six novel pipeline programs at the 2011 American Association for Cancer Research (AACR)/National Cancer Institute (NCI)/European Organization for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics taking place November 12-16, 2011, in San Francisco, California.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

MM-398MM-398 is a novel, stable nanotherapeutic encapsulation of irinotecan.  The U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for use in the treatment of pancreatic cancer.  PharmaEngine, Inc. has rights to develop and commercialize MM-398 in Taiwan under the designation PEP02.  Title:  Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan

Poster Session: Topoisomerase Inhibitors

Number: C207

Date/Time: Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestMM-121 MM-121 is a monoclonal antibody designed to block signaling through the ErbB3 (HER3) receptor. MM-121, in partnership with Sanofi, is in clinical development in patients with breast, lung and ovarian cancer.Title:  Targeting ErbB3 (HER3) and EGFR in Lung Cancer Patients: A Phase I Trial of MM-121 in Combination with Erlotinib in Patients with Non-Small Cell Lung Cancer (NSCLC)

Poster Session: Clinical Trials 3

Number: C27

Date/Time: Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestMM-111MM-111 is a novel bispecific antibody against ErbB3 (HER3), using an ErbB2 (HER2) targeting arm to enhance avidity and inhibition.  Title:  Optimization of MM-111 and lapatinib dosing regimens using mathematical modeling and quantitative biology

Poster Session: Pharmacokinetics and Pharmacodynamics 3

Number: C118

Date/Time: Tuesday, Nov 15, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Convention Center WestMM-302MM-302 is a nanotherapeutic encapsulation of doxorubicin designed to target ErbB2 (HER2) overexpressing cancer cells, while limiting uptake into non-target cells.Title:  HER2-targeted liposomal doxorubicin, MM-302, has a favorable cardiosafety profile in preclinical models

Poster Session: Novel Assay Technology

Number: C90

Date/Time: Tuesday, Nov 15, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestMM-151MM-151 is a mixture of three fully human monoclonal antibodies directed against distinct non-overlapping epitopes in EGFR.Title:  Elucidating mechanisms of action of MM-151, a mixture of three human antibody antagonists targeting EGFR

Poster Session: Therapeutic Agents: Biological 1

Number: A210

Date/Time: Sunday, Nov 13, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestTitle:  Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic

Poster Session: EGFR / Her2

Number: A144

Date/Time: Sunday, Nov 13, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Center WestMM-141MM-141 is a comprehensive IGF-1R signaling inhibitor that is designed to address the redundancies that occur in tumors where both IGF-1R and ErbB3 (HER3) are activated, an approach intended to improve patient response by blocking survival signaling promoted by two separate pathways. Title:  Therapeutically targeting redundant, growth factor-induced pro-survival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3 (HER3)

Poster Session: Therapeutic Agents: Biological 2

Number: B205

Date/Time: Monday, Nov 14, 2011, 12:30 PM – 2:30 PM

Location: West Hall, Level One, Moscone Convention Center WestAbout MerrimackMerrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):